Jacqueline Pesa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jacqueline Pesa has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
Zia Choudhry
Janssen Scientific Affairs, LLC, Titusville, NJ, USA
5 shared publicationsCarmela Benson
Janssen Scientific Affairs, LLC, Titusville, USA
3 shared publications- Caroline Brethenoux
CulturIntel DBA Human Dot Plus, Irving, USA
3 shared publications - Liliana Gil Valletta
CulturIntel DBA Human Dot Plus, Irving, USA
3 shared publications Louis Jackson
Johnson & Johnson
3 shared publications- Patrick Furey
CulturIntel DBA Human Dot Plus, Irving, USA
3 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 13 (3) , 373-382
Complications and Occurrence of Exacerbations in Patients with Myasthenia Gravis Treated with Oral Corticosteroids
Background Myasthenia gravis is a rare disease characterized by autoantibody-driven impairment of neuromuscular junction activity. Standard-of-care therapy includes oral corticosteroids (OCS), despite associated complications. This study describes OCS-related complications and exacerbations in a real-world myasthenia gravis population. Methods This retrospective longitudinal cohort study leveraged US claims data (January 2016–March 2023; Optum’s de-identified Clinformatics® Data Mart Database) to identify patients with myasthenia gravis (International Classification of Diseases, Tenth Revision, Clinical Modification: G70.00/01). Patients were classified into non-OCS and OCS cohorts; the OCS cohort was further stratified into < 6-month, 6-month, and 12-month exposure groups (≥ 5 mg/day prednisone-equivalent; 12-month follow-up). Inverse probability treatment weighting balanced baseline characteristics. Weighted prevalence ratios of select complications (e.g., diabetes, fracture, hyperlipidemia, hypertension, infection, myocardial infarction, osteoporosis, stroke, glaucoma) and rate/risk ratios for exacerbations were calculated. Results The weighted population included 3297 patients in the non-OCS cohort and 418, 872, and 1243 patients in the < 6-month, 6-month, and 12-month OCS exposure groups, respectively. During follow-up, the < 6-month, 6-month, and 12-month OCS exposure groups had significantly higher infection risk versus non-OCS: weighted prevalence ratios (95% confidence interval) 1.6 (1.1–2.1), 1.5 (1.2–2.0), and 1.6 (1.3–2.0), respectively. Osteoporosis risk was similar in the < 6-month group but higher in the 6- and 12-month groups versus non-OCS: weighted prevalence ratios (95% confidence interval) 1.2 (0.9–1.6), 1.5 (1.2–1.8), and 1.7 (1.4–2.0), respectively. Oral corticosteroid exposure groups had more myasthenia gravis exacerbations during follow-up versus non-OCS. Conclusions After adjusting for observable confounders, OCS exposure within the 12-month initiation period was associated with a higher burden of complications and exacerbations among patients with myasthenia gravis. Graphical Abstract
- 8 July 2026
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 13 (3) , 373-382
Open AccessComplications and Occurrence of Exacerbations in Patients with Myasthenia Gravis Treated with Oral Corticosteroids
Background Myasthenia gravis is a rare disease characterized by autoantibody-driven impairment of neuromuscular junction activity. Standard-of-care therapy includes oral corticosteroids (OCS), despite associated complications. This study describes OCS-related complications and exacerbations in a real-world myasthenia gravis population. Methods This retrospective longitudinal cohort study leveraged US claims data (January 2016–March 2023; Optum’s de-identified Clinformatics® Data Mart Database) to identify patients with myasthenia gravis (International Classification of Diseases, Tenth Revision, Clinical Modification: G70.00/01). Patients were classified into non-OCS and OCS cohorts; the OCS cohort was further stratified into < 6-month, 6-month, and 12-month exposure groups (≥ 5 mg/day prednisone-equivalent; 12-month follow-up). Inverse probability treatment weighting balanced baseline characteristics. Weighted prevalence ratios of select complications (e.g., diabetes, fracture, hyperlipidemia, hypertension, infection, myocardial infarction, osteoporosis, stroke, glaucoma) and rate/risk ratios for exacerbations were calculated. Results The weighted population included 3297 patients in the non-OCS cohort and 418, 872, and 1243 patients in the < 6-month, 6-month, and 12-month OCS exposure groups, respectively. During follow-up, the < 6-month, 6-month, and 12-month OCS exposure groups had significantly higher infection risk versus non-OCS: weighted prevalence ratios (95% confidence interval) 1.6 (1.1–2.1), 1.5 (1.2–2.0), and 1.6 (1.3–2.0), respectively. Osteoporosis risk was similar in the < 6-month group but higher in the 6- and 12-month groups versus non-OCS: weighted prevalence ratios (95% confidence interval) 1.2 (0.9–1.6), 1.5 (1.2–1.8), and 1.7 (1.4–2.0), respectively. Oral corticosteroid exposure groups had more myasthenia gravis exacerbations during follow-up versus non-OCS. Conclusions After adjusting for observable confounders, OCS exposure within the 12-month initiation period was associated with a higher burden of complications and exacerbations among patients with myasthenia gravis. Graphical Abstract
- Open Access
- 12 September 2025
- Published by Wiley in Muscle & Nerve
- Vol. 72 (5) , 1143-1151
Association of Race and Social Determinants of Health With Exacerbations in Generalized Myasthenia Gravis
Introduction/Aims: While racial/ethnic disparities exist across many disease states, their influence on the risk of adverse clinical outcomes in large populations of generalized myasthenia gravis (gMG) patients has not been extensively studied. This study assessed the association between race/ethnicity and MG exacerbation risk and examined the potential role of social determinants of health (SDOH). Methods: This retrospective cohort study utilized data from HealthVerity; a large, de‐identified, US insurance claims database. Eligible patients were adults with gMG (≥ 2 MG diagnosis code claims, excluding patients with only ophthalmologic specialist visits on/before index date). Inverse probability of treatment weighting using baseline variables was constructed with multinomial distribution for race/ethnicity (Asian/Black/Hispanic/White). Incidence rate ratio (IRR) for ≥ 1 MG exacerbation (defined as an inpatient episode with MG as admitting diagnosis) during follow‐up was assessed using a generalized estimating equations model, using “White” as the reference. A subset of patients was linked with SDOH variables by residential ZIP code (income‐per‐capita and percentage of population without health insurance coverage) using the Agency for Healthcare Research and Quality database, and MG exacerbation risk adjusted. Results: Of 10,981 gMG patients, 5147 had linked SDOH data. Weighted risk of MG exacerbations was significantly higher among Black versus White patients (IRR 1.21; 95% confidence interval 1.05–1.39). The association remained after controlling for income and/or health insurance coverage. Discussion: Potential racial disparities exist in the occurrence of MG exacerbations. Further investigation of potential drivers is warranted. At‐risk populations should be a focus for healthcare and patient support provision.
- 12 September 2025
- Published by Wiley in Muscle & Nerve
- Vol. 72 (5) , 1143-1151
Open AccessAssociation of Race and Social Determinants of Health With Exacerbations in Generalized Myasthenia Gravis
Introduction/Aims: While racial/ethnic disparities exist across many disease states, their influence on the risk of adverse clinical outcomes in large populations of generalized myasthenia gravis (gMG) patients has not been extensively studied. This study assessed the association between race/ethnicity and MG exacerbation risk and examined the potential role of social determinants of health (SDOH). Methods: This retrospective cohort study utilized data from HealthVerity; a large, de‐identified, US insurance claims database. Eligible patients were adults with gMG (≥ 2 MG diagnosis code claims, excluding patients with only ophthalmologic specialist visits on/before index date). Inverse probability of treatment weighting using baseline variables was constructed with multinomial distribution for race/ethnicity (Asian/Black/Hispanic/White). Incidence rate ratio (IRR) for ≥ 1 MG exacerbation (defined as an inpatient episode with MG as admitting diagnosis) during follow‐up was assessed using a generalized estimating equations model, using “White” as the reference. A subset of patients was linked with SDOH variables by residential ZIP code (income‐per‐capita and percentage of population without health insurance coverage) using the Agency for Healthcare Research and Quality database, and MG exacerbation risk adjusted. Results: Of 10,981 gMG patients, 5147 had linked SDOH data. Weighted risk of MG exacerbations was significantly higher among Black versus White patients (IRR 1.21; 95% confidence interval 1.05–1.39). The association remained after controlling for income and/or health insurance coverage. Discussion: Potential racial disparities exist in the occurrence of MG exacerbations. Further investigation of potential drivers is warranted. At‐risk populations should be a focus for healthcare and patient support provision.
- Open Access
- 1 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 11108
Factors associated with increased severity of generalized myasthenia gravis among patients in the United States and Europe
Among individuals with generalized myasthenia gravis (gMG), risk factors for increased severity over time are unknown. This study examined the association between demographic and clinical variables and patient progression to a more severe MG Foundation of America (MGFA) classification. Data were drawn from the Adelphi Real World myasthenia gravis Disease Specific Programme™, a cross-sectional survey capturing retrospective data from patients' medical histories. Among 421 individuals, 16% experienced increased gMG severity (progression to higher MGFA class between diagnosis and the time of the survey, 1-7 years later) and for 84%, gMG was stable/improved (MGFA class the same/lower). Logistic elastic net regression determined that increased severity was associated with the occurrence of prior misdiagnosis. Bivariate analyses indicated significant associations between increased severity and longer time between symptom onset and (a) the first consultation with a healthcare practitioner and (b) MG diagnosis. Increased severity was also associated with older age and presence of specific symptoms at diagnosis. gMG stability/improvement was associated with employment status and general fatigue at diagnosis. There is a need for prompt and accurate diagnosis and improved treatment options with the potential to increase the likelihood of stability/improvement for gMG patients.
- 1 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 11108
Open AccessFactors associated with increased severity of generalized myasthenia gravis among patients in the United States and Europe
Among individuals with generalized myasthenia gravis (gMG), risk factors for increased severity over time are unknown. This study examined the association between demographic and clinical variables and patient progression to a more severe MG Foundation of America (MGFA) classification. Data were drawn from the Adelphi Real World myasthenia gravis Disease Specific Programme™, a cross-sectional survey capturing retrospective data from patients' medical histories. Among 421 individuals, 16% experienced increased gMG severity (progression to higher MGFA class between diagnosis and the time of the survey, 1-7 years later) and for 84%, gMG was stable/improved (MGFA class the same/lower). Logistic elastic net regression determined that increased severity was associated with the occurrence of prior misdiagnosis. Bivariate analyses indicated significant associations between increased severity and longer time between symptom onset and (a) the first consultation with a healthcare practitioner and (b) MG diagnosis. Increased severity was also associated with older age and presence of specific symptoms at diagnosis. gMG stability/improvement was associated with employment status and general fatigue at diagnosis. There is a need for prompt and accurate diagnosis and improved treatment options with the potential to increase the likelihood of stability/improvement for gMG patients.
- Open Access
- 17 December 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (12)
Design of and Early Insights From a Generalized Myasthenia Gravis Patient Engagement Research Council
Background and Aims: An exploratory focus group study was conducted to better understand the needs of patients living with generalized myasthenia gravis (gMG).Methods: US‐based adults with gMG and caregivers of patients with gMG participated in a Patient Engagement Research Council between August 2022 and January 2023. The study consisted of a 15‐min prework survey, followed by virtual focus groups facilitated using a semi‐structured interview guide. Data concepts were identified using conversational analysis and by direct observation. All transcripts were coded based on concepts using a qualitative research analysis program (MaxQDA).Results: 16 participants (13 patients, three caregivers) were recruited. Participants reported impact on daily activities, fatigue, and psychosocial problems. Many participants experienced delayed diagnosis and difficulty accessing specialist care. Participants described multiple barriers related to their gMG, including barriers to treatment, access‐related issues, and communication disconnect between patients and healthcare professionals. Achieving stable disease was the most important goal. There was a preference for the autonomy of self‐administered medications at home versus infusions. Study insights led to recommendations to guide patient and healthcare professional education.Conclusion: The study illustrates the need to improve access to specialist care, achieve earlier diagnosis, prioritize patients' preferences in disease management, and develop treatments that improve outcomes without additional burden.Patient or Public Contribution: The data collected in this study was provided by the focus group participants, which included patients and caregivers of those with myasthenia gravis.
- 17 December 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (12)
Open AccessDesign of and Early Insights From a Generalized Myasthenia Gravis Patient Engagement Research Council
Background and Aims: An exploratory focus group study was conducted to better understand the needs of patients living with generalized myasthenia gravis (gMG).Methods: US‐based adults with gMG and caregivers of patients with gMG participated in a Patient Engagement Research Council between August 2022 and January 2023. The study consisted of a 15‐min prework survey, followed by virtual focus groups facilitated using a semi‐structured interview guide. Data concepts were identified using conversational analysis and by direct observation. All transcripts were coded based on concepts using a qualitative research analysis program (MaxQDA).Results: 16 participants (13 patients, three caregivers) were recruited. Participants reported impact on daily activities, fatigue, and psychosocial problems. Many participants experienced delayed diagnosis and difficulty accessing specialist care. Participants described multiple barriers related to their gMG, including barriers to treatment, access‐related issues, and communication disconnect between patients and healthcare professionals. Achieving stable disease was the most important goal. There was a preference for the autonomy of self‐administered medications at home versus infusions. Study insights led to recommendations to guide patient and healthcare professional education.Conclusion: The study illustrates the need to improve access to specialist care, achieve earlier diagnosis, prioritize patients' preferences in disease management, and develop treatments that improve outcomes without additional burden.Patient or Public Contribution: The data collected in this study was provided by the focus group participants, which included patients and caregivers of those with myasthenia gravis.
- Open Access
- 12 October 2024
- Published by Springer Nature in BMC Neurology
- Vol. 24 (1) , 1-9
Clinical characteristics and impairment of activities of daily living among patients with myasthenia gravis with differing degrees of muscle weakness: a real-world study of patients in the US and five European countries
Real-world data were employed to determine clinical characteristics of patients with myasthenia gravis (MG) with differing degrees of muscle weakness, as defined using the Myasthenia Gravis Foundation of America (MGFA) classification system. Data were drawn from the Adelphi MG Disease Specific Programme (DSP)™, a multinational (United States, France, Germany, Italy, Spain, United Kingdom) survey completed by physicians and their patients with MG in 2020. The association between MGFA class and impairment in activities of daily living (ADL) was tested using linear regression adjusting for sex and Charlson Comorbidity Index. Bivariate comparisons were performed for each individual item. A range of other clinical characteristics were also explored according to MGFA class. Among 1232 patients, those in MGFA class I had significantly lower ADL impairment versus class II or III/IV (adjusted for sex and Charlson Comorbidity Index) (p < 0.01). However, heterogeneity occurred within each MGFA class. Bulbar symptoms (impaired speech, difficulty swallowing, and/or difficulty chewing/choking on food) were reported in some class I patients (mild in 1.1–1.9% and moderate in 0.3–1.1% of patients) and class II patients (mild in 8.5–16.4%, moderate in 4.7–7.4%, and severe in 0.3–0.9% of patients), and shortness of breath was reported in some class I (mild in 0.5% of patients) and class II patients (mild in 9.8%, moderate in 4.8%, and severe in 0.3% of patients). Conversely, in 11.2–19.2% of class III/IV patients, bulbar symptoms and shortness of breath reported were only mild in severity. In line with this finding, despite significant correlations between MGFA class and several clinical characteristics, patients across every class were at risk of experiencing myasthenic crisis or hospitalization, experiencing comorbidities including anxiety and depression, and not being in remission. Although MGFA class correlates with greater ADL impairment and presence of other clinical characteristics, there is variability between patients in each class in terms of symptoms experienced, overall disease burden, and the precise nature of ADL impairment.
- 12 October 2024
- Published by Springer Nature in BMC Neurology
- Vol. 24 (1) , 1-9
Open AccessClinical characteristics and impairment of activities of daily living among patients with myasthenia gravis with differing degrees of muscle weakness: a real-world study of patients in the US and five European countries
Real-world data were employed to determine clinical characteristics of patients with myasthenia gravis (MG) with differing degrees of muscle weakness, as defined using the Myasthenia Gravis Foundation of America (MGFA) classification system. Data were drawn from the Adelphi MG Disease Specific Programme (DSP)™, a multinational (United States, France, Germany, Italy, Spain, United Kingdom) survey completed by physicians and their patients with MG in 2020. The association between MGFA class and impairment in activities of daily living (ADL) was tested using linear regression adjusting for sex and Charlson Comorbidity Index. Bivariate comparisons were performed for each individual item. A range of other clinical characteristics were also explored according to MGFA class. Among 1232 patients, those in MGFA class I had significantly lower ADL impairment versus class II or III/IV (adjusted for sex and Charlson Comorbidity Index) (p < 0.01). However, heterogeneity occurred within each MGFA class. Bulbar symptoms (impaired speech, difficulty swallowing, and/or difficulty chewing/choking on food) were reported in some class I patients (mild in 1.1–1.9% and moderate in 0.3–1.1% of patients) and class II patients (mild in 8.5–16.4%, moderate in 4.7–7.4%, and severe in 0.3–0.9% of patients), and shortness of breath was reported in some class I (mild in 0.5% of patients) and class II patients (mild in 9.8%, moderate in 4.8%, and severe in 0.3% of patients). Conversely, in 11.2–19.2% of class III/IV patients, bulbar symptoms and shortness of breath reported were only mild in severity. In line with this finding, despite significant correlations between MGFA class and several clinical characteristics, patients across every class were at risk of experiencing myasthenic crisis or hospitalization, experiencing comorbidities including anxiety and depression, and not being in remission. Although MGFA class correlates with greater ADL impairment and presence of other clinical characteristics, there is variability between patients in each class in terms of symptoms experienced, overall disease burden, and the precise nature of ADL impairment.
- Open Access
- 24 September 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (9) , e70081
Patient and care partner perspectives and preferences related to myasthenia gravis treatment: A qualitative study
Background and Aims: Due to the high symptom and treatment burden in myasthenia gravis (MG), understanding patient and care partner perspectives and preferences is crucial.Methods: This study used voice analysis and virtual focus groups to understand patient and care partner experiences with MG‐related symptoms, treatments, and preferences. The voice analysis via social media listening used artificial intelligence‐powered tools to gather and structure public digital conversations on MG. Focus groups included people living with MG and care partners who completed a questionnaire and participated in a 1‐h virtual session facilitated using a semi‐structured interview guide. Qualitative data were aggregated, transcribed, and thematically analyzed.Results: The voice analysis examined 11,554 posts from 8321 individuals, discussing MG symptoms, treatments, and burden. Of 7563 symptom‐related posts, 5902 (78%) conveyed negative, 1427 (19%) neutral, and 234 (3%) positive sentiment. The most frequently mentioned symptoms were categorized as dysarthria, muscle weakness, and dysphagia. MG treatment sentiment analysis identified 6667 posts (67%) as neutral, 2887 (29%) as negative, and 350 (4%) as positive. For the focus groups, 15 individuals (12 patients and 3 care partners) completed the questionnaire and 14 participated in the virtual focus group sessions. The 15 participants who completed the questionnaire prioritized treatment convenience, symptom control for improved quality of life, and preventing potential MG crises in their current treatment. New treatment expectations included increased effectiveness, less frequent dosing, faster onset, and fewer side effects. Participants were also receptive to wearable medication delivery systems placed on the body and valued direct involvement in treatment decisions.Conclusion: Patients and care partners are often negatively impacted by MG symptoms and value convenient and fast‐acting treatments that control symptoms with minimal side effects. Considering patient preferences may help optimize treatment decisions and improve patients' overall well‐being and satisfaction in their care.
- 24 September 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (9) , e70081
Open AccessPatient and care partner perspectives and preferences related to myasthenia gravis treatment: A qualitative study
Background and Aims: Due to the high symptom and treatment burden in myasthenia gravis (MG), understanding patient and care partner perspectives and preferences is crucial.Methods: This study used voice analysis and virtual focus groups to understand patient and care partner experiences with MG‐related symptoms, treatments, and preferences. The voice analysis via social media listening used artificial intelligence‐powered tools to gather and structure public digital conversations on MG. Focus groups included people living with MG and care partners who completed a questionnaire and participated in a 1‐h virtual session facilitated using a semi‐structured interview guide. Qualitative data were aggregated, transcribed, and thematically analyzed.Results: The voice analysis examined 11,554 posts from 8321 individuals, discussing MG symptoms, treatments, and burden. Of 7563 symptom‐related posts, 5902 (78%) conveyed negative, 1427 (19%) neutral, and 234 (3%) positive sentiment. The most frequently mentioned symptoms were categorized as dysarthria, muscle weakness, and dysphagia. MG treatment sentiment analysis identified 6667 posts (67%) as neutral, 2887 (29%) as negative, and 350 (4%) as positive. For the focus groups, 15 individuals (12 patients and 3 care partners) completed the questionnaire and 14 participated in the virtual focus group sessions. The 15 participants who completed the questionnaire prioritized treatment convenience, symptom control for improved quality of life, and preventing potential MG crises in their current treatment. New treatment expectations included increased effectiveness, less frequent dosing, faster onset, and fewer side effects. Participants were also receptive to wearable medication delivery systems placed on the body and valued direct involvement in treatment decisions.Conclusion: Patients and care partners are often negatively impacted by MG symptoms and value convenient and fast‐acting treatments that control symptoms with minimal side effects. Considering patient preferences may help optimize treatment decisions and improve patients' overall well‐being and satisfaction in their care.
- Open Access
- 13 July 2024
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 22 (5) , 735-747
Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective
Background High healthcare costs could arise from unmet needs. This study used random forest (RF) and regression methods to identify predictors of high costs from a US payer perspective in patients newly diagnosed with generalized myasthenia gravis (gMG). Methods Adults with gMG (first diagnosis = index) were selected from the IQVIA PharMetrics® Plus database (2017–2021). Predictors of high healthcare costs were measured 12 months pre-index (main cohort) and during both the 12 months pre- and post-index (subgroup). Top 50 predictors of high costs [≥ $9404 (main cohort) and ≥ $9159 (subgroup) per-patient-per-month] were identified with RF models; the magnitude and direction of association were estimated with multivariable modified Poisson regression models. Results The main cohort and subgroup included 2739 and 1638 patients, respectively. In RF analysis, the most important predictors of high costs before/on the index date were index MG exacerbation, all-cause inpatient admission, and number of days with corticosteroids. After the index date, these were immunoglobulin and monoclonal antibody use and number of all-cause outpatient visits and MG-related encounters. Adjusting for the top 50 predictors, post-index immunoglobulin use increased the risk of high costs by 261%, monoclonal antibody use by 135%, index MG exacerbation by 78%, and pre-index all-cause inpatient admission by 27% (all p < 0.05). Conclusions This analysis links patient characteristics both before the formal MG diagnosis and in the first year to high future healthcare costs. Findings may help inform payers on cost-saving strategies, and providers can potentially shift to targeted treatment approaches to reduce the clinical and economic burden of gMG.
- 13 July 2024
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 22 (5) , 735-747
Open AccessPredictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective
Background High healthcare costs could arise from unmet needs. This study used random forest (RF) and regression methods to identify predictors of high costs from a US payer perspective in patients newly diagnosed with generalized myasthenia gravis (gMG). Methods Adults with gMG (first diagnosis = index) were selected from the IQVIA PharMetrics® Plus database (2017–2021). Predictors of high healthcare costs were measured 12 months pre-index (main cohort) and during both the 12 months pre- and post-index (subgroup). Top 50 predictors of high costs [≥ $9404 (main cohort) and ≥ $9159 (subgroup) per-patient-per-month] were identified with RF models; the magnitude and direction of association were estimated with multivariable modified Poisson regression models. Results The main cohort and subgroup included 2739 and 1638 patients, respectively. In RF analysis, the most important predictors of high costs before/on the index date were index MG exacerbation, all-cause inpatient admission, and number of days with corticosteroids. After the index date, these were immunoglobulin and monoclonal antibody use and number of all-cause outpatient visits and MG-related encounters. Adjusting for the top 50 predictors, post-index immunoglobulin use increased the risk of high costs by 261%, monoclonal antibody use by 135%, index MG exacerbation by 78%, and pre-index all-cause inpatient admission by 27% (all p < 0.05). Conclusions This analysis links patient characteristics both before the formal MG diagnosis and in the first year to high future healthcare costs. Findings may help inform payers on cost-saving strategies, and providers can potentially shift to targeted treatment approaches to reduce the clinical and economic burden of gMG.
- Open Access
- 27 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Patient perceptions of disease burden and treatment of myasthenia gravis based on sentiment analysis of digital conversations
Myasthenia gravis (MG) is a rare, autoimmune, antibody-mediated, neuromuscular disease. This study analyzed digital conversations about MG to explore unprovoked perspectives. Advanced search, data extraction, and artificial intelligence-powered algorithms were used to harvest, mine, and structure public domain digital conversations about MG from US Internet Protocol addresses (August 2021 to August 2022). Thematic analyses examined topics, mindsets, and sentiments/key drivers via natural language processing and text analytics. Findings were described by sex/gender and treatment experience with steroids or intravenous immunoglobulin (IVIg). The 13,234 conversations were extracted from message boards (51%), social media networks (22%), topical sites (21%), and blogs (6%). Sex/gender was confirmed as female in 5703 and male in 2781 conversations, and treatment experience was with steroids in 3255 and IVIg in 2106 conversations. Topics focused on diagnosis (29%), living with MG (28%), symptoms (24%), and treatment (19%). Within 3176 conversations about symptoms, eye problems (21%), facial muscle problems (18%), and fatigue (18%) were most commonly described. Negative sentiments about MG were expressed in 59% of conversations, with only 2% considered positive. Negative conversations were dominated by themes of impact on life (29%), misdiagnosis problems (27%), treatment issues (24%), and symptom severity (20%). Impact on life was a key driver of negativity in conversations by both men (27%) and women (34%), and treatment issues was a dominant theme in conversations by steroid-treated (29%) and IVIg-treated (31%) patients. Of 1382 conversations discussing treatment barriers, 36% focused on side effects, 33% on lack of efficacy, 21% on misdiagnosis, and 10% on cost/insurance. Side effects formed the main barrier in conversations by both steroid-treated and IVIg-treated patients. Capturing the patient voice via digital conversations reveals a high degree of concern related to burden of disease, misdiagnosis, and common MG treatments among those with MG, pointing to a need for treatment options that can improve quality of life.
- 27 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Open AccessPatient perceptions of disease burden and treatment of myasthenia gravis based on sentiment analysis of digital conversations
Myasthenia gravis (MG) is a rare, autoimmune, antibody-mediated, neuromuscular disease. This study analyzed digital conversations about MG to explore unprovoked perspectives. Advanced search, data extraction, and artificial intelligence-powered algorithms were used to harvest, mine, and structure public domain digital conversations about MG from US Internet Protocol addresses (August 2021 to August 2022). Thematic analyses examined topics, mindsets, and sentiments/key drivers via natural language processing and text analytics. Findings were described by sex/gender and treatment experience with steroids or intravenous immunoglobulin (IVIg). The 13,234 conversations were extracted from message boards (51%), social media networks (22%), topical sites (21%), and blogs (6%). Sex/gender was confirmed as female in 5703 and male in 2781 conversations, and treatment experience was with steroids in 3255 and IVIg in 2106 conversations. Topics focused on diagnosis (29%), living with MG (28%), symptoms (24%), and treatment (19%). Within 3176 conversations about symptoms, eye problems (21%), facial muscle problems (18%), and fatigue (18%) were most commonly described. Negative sentiments about MG were expressed in 59% of conversations, with only 2% considered positive. Negative conversations were dominated by themes of impact on life (29%), misdiagnosis problems (27%), treatment issues (24%), and symptom severity (20%). Impact on life was a key driver of negativity in conversations by both men (27%) and women (34%), and treatment issues was a dominant theme in conversations by steroid-treated (29%) and IVIg-treated (31%) patients. Of 1382 conversations discussing treatment barriers, 36% focused on side effects, 33% on lack of efficacy, 21% on misdiagnosis, and 10% on cost/insurance. Side effects formed the main barrier in conversations by both steroid-treated and IVIg-treated patients. Capturing the patient voice via digital conversations reveals a high degree of concern related to burden of disease, misdiagnosis, and common MG treatments among those with MG, pointing to a need for treatment options that can improve quality of life.
- 29 September 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 261, 170-177
Racial disparities in utilization of first-generation versus second-generation long-acting injectable antipsychotics in Medicaid beneficiaries with schizophrenia
- 29 September 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 261, 170-177
Racial disparities in utilization of first-generation versus second-generation long-acting injectable antipsychotics in Medicaid beneficiaries with schizophrenia